The project
The study aims to understand which treatment outcomes are most important to patients with locally advanced, unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). It will also explore the patient’s perspectives and preferences regarding radioligand therapy, a type of cancer treatment that uses radiation to target cancer cells.
What are you going to do?
Eligible participants will take part in a 60 minute online/telephone interview about their treatment experiences and outcomes and will provide feedback on radioligand therapy. Eligible participants will receive £49 for completing the interview and £49 for providing confirmation of diagnosis. The study is strictly for research purposes, with no sales or promotional activities.
Why is this research important?
This research aims to understand which treatment outcomes matter most to people living with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. It will also explore patients’ views on radioligand therapy (RLT), an emerging treatment that uses targeted radiation to attack cancer cells. The findings could help ensure that future treatments and research are better aligned with patients’ needs, priorities, and preferences.
How do I get involved?
Individuals will be eligible to participate if they:
- Be based in the UK and fluent in English.
- Be aged 18 years or older.
- Have a confirmed diagnosis of either:
- Locally advanced, unresectable PDAC
- Metastatic PDAC.
- Have received at least one prior treatment for locally advanced, unresectable or metastatic PDAC.
- Be willing and able to provide informed consent before taking part.
- Be able to verify their diagnosis through clinical documentation, such as medical records, patient portal
- Screenshots or confirmation from a treating healthcare professional.
- Be willing and able to participate in a 60 minute online or telephone interview, using a computer or laptop at a convenient time, and to have the interview recorded.
Participants would not be eligible if they:
- Are unable to adhere to the requirements of the study
- Have another malignancy for which they are currently receiving treatment.
No scientific background or prior experience is needed to take part in this opportunity.
Next steps
If you are interested in participating in the study or would like more information, you can complete our expression of interest form here.